grant
Project 3 Determinants of Vaccine Efficacy
Organization UNIV OF MASSACHUSETTS MED SCH WORCESTERLocation WORCESTER, UNITED STATESPosted 20 Aug 2024Deadline 31 May 2029
NIHUS FederalResearch GrantFY2025AddressAffectAnimal ModelAnimal Models and Related StudiesAnimalsAntitubercular AgentsAttentionBCG LiveBCG immunizationBCG vaccinationBCG-vaccinatedBacille Calmette-Guerin vaccinatedBacille Calmette-Guerin vaccinationBacille Calmette-GuérinBacillus Calmette GuérinBacillus Calmette-Guerin vaccinationBacillus Calmette-Guérin vaccinationBacteriaBloodBlood Reticuloendothelial SystemCellular Immune FunctionClinicalCollaborationsControl LocusDataDrug resistance in MtbDrug resistance in Mycobacterium TuberculosisDrug resistant M TuberculosisDrug resistant MtbDrug resistant Mycobacteria TuberculosisEngineeringEvaluationExposure toExpression SignatureFundingGene Expression ProfileGene PoolGene TranscriptionGeneticGenetic DiversityGenetic PolymorphismGenetic TranscriptionGenetic VariationGenus MycobacteriumGoalsHandHumanHuman GeneticsImmuneImmune responseImmunesImmunityImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsInbreedingInfantKnowledgeLaboratory miceLungLung Respiratory SystemLung TBLung TuberculosisM . tuberculosis resistanceM tbM tuberculosisM tuberculosis infectionM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMTB infectionMTB vaccineMammalian GeneticsMeasuresMediatingMiceMice MammalsModern ManMolecularMorbidityMorbidity - disease rateMouse StrainsMtb drug resistanceMtb resistanceMurineMusMycobacteriumMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionMycobacterium tuberculosis resistanceNatureOutcomePathway interactionsPersonsPolyproteinsPopulationPopulation HeterogeneityPre-Clinical ModelPreclinical ModelsProductionPulmonary TBPulmonary TuberculosisQTLQuantitative Trait LociRNA ExpressionReportingResearchRoleSamplingSouth AfricaSystemTB infectionTB vaccineTestingTranscriptionTranslatingTuberculosisTuberculosis VaccinesTuberculostatic AgentsVaccinatedVaccinationVaccination acquired immunityVaccination induced immunityVaccine ProductionVaccine for TBVaccine for TuberculosisVaccinesVariantVariationViral VectorWorkanti-TBanti-TB vaccineanti-tuberculosisantiTBcausal allelecausal genecausal mutationcausal variantcausative mutationcausative variantcohortcytokinedesigndesigningdisseminated TBdisseminated tuberculosisdiverse populationsdrug resistance M Tuberculosisdrug resistance Mycobacteria Tuberculosisdrug resistant M.tbevaluate vaccinesgene expression patterngene expression signaturegene locusgenetic locusgenomic locationgenomic locushandsheterogeneous populationhost responseimmune functionimmune system responseimmunoresponseimprovedinfection due to Mycobacterium tuberculosisinterestmodel of animalmortalitymouse modelmtbmurine modelnew vaccinesnext generation vaccinesnovelnovel vaccinespathwayplasmid vaccinepolymorphismpopulation diversitypreventpreventingproduce vaccinesprogramsprospectiveresistance in M . tuberculosisresistance in Mycobacterium tuberculosisresistant M . tuberculosisresistant Mtbresistant Mycobacterium tuberculosisresponsesocial rolesuccesstranscriptional profiletranscriptional signaturetranslation to humanstuberculosis infectiontuberculous spondyloarthropathyvaccination studyvaccination trialvaccine acquired immunityvaccine against M. tuberculosisvaccine against Mtbvaccine against Mycobacterium tuberculosisvaccine against TBvaccine against tuberculosisvaccine associated immunityvaccine candidatevaccine candidates against tuberculosisvaccine efficacyvaccine evaluationvaccine responsevaccine responsivenessvaccine screeningvaccine strategyvaccine studyvaccine testingvaccine trialvaccine-induced immunityvaccine-induced protectionvaccine-induced responsevector vaccine
Description preview
Project 3: Determinants of Vaccine Efficacy (Project Leader: Behar)
Abstract
The bacterium Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB), which is a leading cause of
global morbidity and mortality. Given the rapid spread of drug resistant Mtb strains, the long-term solution
must be a safe and effective vaccine. Much well-deserved…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click